- In February 2024, FUJIFILM Healthcare Americas Corporation announced that it’s Synapse VNA and Synapse Radiology PACS solutions (in Asia/Oceania) were ranked #1 in the 2024 Best in KLAS Awards: Software and Services. The recognition, based on insights from KLAS Research, highlights companies excelling in improving patient care through their software and services
- In February 2023, Avicenna.AI, a medical imaging company, launched CINA-iPE, a CE-marked AI tool designed to analyze chest CT scans for the presence of incidental pulmonary embolism. This marks the debut of CINA Incidental, a new suite of imaging solutions from Avicenna.AI that detects unsuspected pathologies on CT scans
- In October 2022, GE Healthcare and Tribun Health formed a partnership aimed at providing digital pathology departmental solutions that offer healthcare providers a more comprehensive view of patient records. The collaboration focuses on integrating Tribun's Health Suite data into GE Healthcare’s solutions, including its vendor-neutral archive (VNA)
- In April 2022, FUJIFILM Holdings Corporation teamed up with the United States Department of Defense (DoD) to implement its Synapse PACS solution in U.S. Naval and Air Force medical treatment facilities. The collaboration aims to standardize the facilities' digital imaging networks, specifically the Picture Archiving and Communication Systems (DIN-PACS), for the next 10 years
- In March 2022, Philips introduced Ultrasound Workspace at the American College of Cardiology’s Annual Scientific Session & Expo (ACC2022). The solution is a vendor-neutral 2D/3D echocardiography analysis, viewing, and reporting platform, designed to enhance echocardiography analysis and streamline the reporting process
Frequently Asked Questions
The market is segmented based on Global Vendor Neutral Archive (VNA) Market Segmentation, By Delivery Mode (On-Premise VNA, Hybrid VNA, and Fully Cloud-Hosted VNA), Procurement Mode (Departmental VNA, Multi-Departmental VNA, and Multi-Site VNA), Imaging Modality (Angiography, Mammography, Computed Tomography, Digital Fluoroscopy, Digital Radiography, Magnetic Resonance Imaging, Nuclear Imaging, Ultrasound, and Other), Usage Model (Single Department, Multiple Departments, and Multiple Sites), Player Type (PACS, Independent Software, and Infrastructure) – Industry Trends and Forecast to 2032
.
The Global Vendor Neutral Archive Vna Market size was valued at USD 3.68 USD Billion in 2024.
The Global Vendor Neutral Archive Vna Market is projected to grow at a CAGR of 5.13% during the forecast period of 2025 to 2032.
The major players operating in the market include Pfizer, GlaxoSmithKline, Novartis, Mylan, Teva Pharmaceutical Industries, Sanofi, AstraZeneca, Johnson & Johnson Private Limited, Merck & Co., F. Hoffmann-La Roche, Baxter, Bayer, Eli Lilly and Company, Sun Pharmaceutical Industries, Aurobindo Pharma, Lupin, Allergan, AbbVie, Abbott, Bausch Health Companies.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
